Evaluation of noncytotoxic DNMT1-depleting therapy in patients with myelodysplastic syndromes

BACKGROUND. Mutational inactivation in cancer of key apoptotic pathway components, such as TP53/p53, undermines cytotoxic therapies that aim to increase apoptosis. Accordingly, TP53 mutations are reproducibly associated with poor treatment outcomes. Moreover, cytotoxic treatments destroy normal stem...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:J Clin Invest
Autores principales: Saunthararajah, Yogen, Sekeres, Mikkael, Advani, Anjali, Mahfouz, Reda, Durkin, Lisa, Radivoyevitch, Tomas, Englehaupt, Ricki, Juersivich, Joy, Cooper, Kathleen, Husseinzadeh, Holleh, Przychodzen, Bartlomiej, Rump, Matthew, Hobson, Sean, Earl, Marc, Sobecks, Ronald, Dean, Robert, Reu, Frederic, Tiu, Ramon, Hamilton, Betty, Copelan, Edward, Lichtin, Alan, Hsi, Eric, Kalaycio, Matt, Maciejewski, Jaroslaw
Formato: Artigo
Lenguaje:Inglês
Publicado: American Society for Clinical Investigation 2015
Materias:
Clinical Medicine
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC4362268/
https://ncbi.nlm.nih.gov/pubmed/25621498
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/JCI78789
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares